WO2021191353A3 - Verfahren zur bereitstellung eines vakzins gegen coronaviren - Google Patents
Verfahren zur bereitstellung eines vakzins gegen coronaviren Download PDFInfo
- Publication number
- WO2021191353A3 WO2021191353A3 PCT/EP2021/057746 EP2021057746W WO2021191353A3 WO 2021191353 A3 WO2021191353 A3 WO 2021191353A3 EP 2021057746 W EP2021057746 W EP 2021057746W WO 2021191353 A3 WO2021191353 A3 WO 2021191353A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- methods
- providing
- vaccine against
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000711573 Coronaviridae Species 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 5
- 239000000443 aerosol Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180024625.XA CN115443149A (zh) | 2020-03-26 | 2021-03-25 | 用于提供抗冠状病毒的疫苗的方法 |
JP2022558141A JP2023518886A (ja) | 2020-03-26 | 2021-03-25 | ワクチン提供方法 |
EP21715228.9A EP4126024A2 (de) | 2020-03-26 | 2021-03-25 | Verfahren zur bereitstellung eines vakzins gegen coronaviren |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020108453.6 | 2020-03-26 | ||
DE102020108453.6A DE102020108453A1 (de) | 2020-03-26 | 2020-03-26 | Verfahren zur Bereitstellung eines Vakzins |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021191353A2 WO2021191353A2 (de) | 2021-09-30 |
WO2021191353A3 true WO2021191353A3 (de) | 2022-09-01 |
Family
ID=75278035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/057746 WO2021191353A2 (de) | 2020-03-26 | 2021-03-25 | Verfahren zur bereitstellung eines vakzins |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4126024A2 (de) |
JP (1) | JP2023518886A (de) |
CN (1) | CN115443149A (de) |
DE (1) | DE102020108453A1 (de) |
WO (1) | WO2021191353A2 (de) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016130569A1 (en) * | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
-
2020
- 2020-03-26 DE DE102020108453.6A patent/DE102020108453A1/de active Pending
-
2021
- 2021-03-25 CN CN202180024625.XA patent/CN115443149A/zh active Pending
- 2021-03-25 WO PCT/EP2021/057746 patent/WO2021191353A2/de active Application Filing
- 2021-03-25 EP EP21715228.9A patent/EP4126024A2/de active Pending
- 2021-03-25 JP JP2022558141A patent/JP2023518886A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016130569A1 (en) * | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
Non-Patent Citations (4)
Title |
---|
LI YEN-DER ET AL: "Coronavirus vaccine development: from SARS and MERS to COVID-19", JOURNAL OF BIOMEDICAL SCIENCE, 20 December 2020 (2020-12-20), pages 1 - 23, XP055819408, Retrieved from the Internet <URL:https://jbiomedsci.biomedcentral.com/track/pdf/10.1186/s12929-020-00695-2.pdf> [retrieved on 20210629], DOI: 10.1186/s12929-020-00695-2 * |
LIN JIANG-TAO ET AL: "Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine", ANTIVIR. THER., vol. 12, no. 7, 1 January 2007 (2007-01-01), pages 1107 - 1113, XP055819262, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/18018769> * |
QU D ET AL: "Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 7, 4 January 2005 (2005-01-04), pages 924 - 931, XP027651769, ISSN: 0264-410X, [retrieved on 20050104] * |
WU FAN ET AL: "A new coronavirus associated with human respiratory disease in China", NATURE, MACMILLAN JOURNALS LTD., ETC, LONDON, vol. 579, no. 7798, 3 February 2020 (2020-02-03), pages 265 - 269, XP037099569, ISSN: 0028-0836, [retrieved on 20200203], DOI: 10.1038/S41586-020-2008-3 * |
Also Published As
Publication number | Publication date |
---|---|
CN115443149A (zh) | 2022-12-06 |
WO2021191353A2 (de) | 2021-09-30 |
EP4126024A2 (de) | 2023-02-08 |
DE102020108453A1 (de) | 2021-09-30 |
JP2023518886A (ja) | 2023-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Balke et al. | Recent advances in the use of plant virus-like particles as vaccines | |
Aligholipour Farzani et al. | Immunological analysis of a CCHFV mRNA vaccine candidate in mouse models | |
CN104144941B (zh) | 以计算方式优化的人和禽h5n1流感的广泛反应性抗原 | |
Kamlangdee et al. | Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene | |
Zimmer | RNA replicons-a new approach for influenza virus immunoprophylaxis | |
Wang et al. | Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models | |
TW202203967A (zh) | 不活化SARS—CoV—2病毒疫苗 | |
Kozak et al. | The integrated consideration of vaccine platforms, adjuvants, and delivery routes for successful vaccine development | |
Chakraborty et al. | SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic | |
Li et al. | Possible targets of pan-coronavirus antiviral strategies for emerging or re-emerging coronaviruses | |
Duman et al. | COVID-19 vaccine candidates and vaccine development platforms available worldwide | |
Deviatkin et al. | Universal flu mRNA vaccine: promises, prospects, and problems | |
Gupta et al. | Recent developments in vaccine design: From live vaccines to recombinant toxin vaccines | |
Farhud et al. | A brief overview of COVID-19 vaccines | |
Khare et al. | SARS-CoV-2 vaccines: types, working principle, and its impact on thrombosis and gastrointestinal disorders | |
BRPI0513741A (pt) | processo de melhoria da imunogeneicidade de um imunogene, antìgeno ou hapteno, complexo imunogênico, ácido nucleico e utilização de um complexo imunogênico | |
WO2021231925A8 (en) | Vaccines for recurrent respiratory papillomatosis and methods of using the same | |
WO2021191353A3 (de) | Verfahren zur bereitstellung eines vakzins gegen coronaviren | |
Zhang et al. | Advanced vaccine design strategies against SARS-CoV-2 and emerging variants | |
Hebel et al. | A survey of mechanisms underlying current and potential COVID‐19 vaccines | |
JP6589159B2 (ja) | 新規ネコモルビリウイルス株、不活化ワクチン製剤、並びにネコモルビリウイルス感染症予防方法 | |
Wang et al. | DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin | |
Chiale et al. | Modified alphavirus-vesiculovirus hybrid vaccine vectors for homologous prime-boost immunotherapy of chronic hepatitis B | |
Robertson et al. | International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety | |
Liu et al. | Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21715228 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2022558141 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 17913822 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021715228 Country of ref document: EP Effective date: 20221026 |